Skip to main content

textochbilcontainer

A BUSINESS MODEL WITH FASTER TIME TO MARKET AND LOWER DEVELOPMENT RISK COMPARED WITH CONVENTIONAL DRUG DEVELOPMENT

textochbilcontainer

OUR CLINICAL pipeline CONSISTS of late stage drug candidates with a combined peak sales potential estimated at USD 350–700

textochbilcontainer

Moberg pharma intends to submit a registration application in Europe in 2021.

textochbilcontainer

We support Barncancerfonden

Moberg Pharma is a rapidly growing Swedish pharmaceutical company commercializing proprietary, acquired and licensed products in the global market. Initially, the company specialized in the treatment of skin diseases, with a focus on treatments for nail fungus.

Stockvalue

Subscribe

Get our latest press releases and reports

 

Latest report

2021-02-09 Moberg Pharmas Year-end report 2020

Calendar/presentations

Next calendar event: 2021-05-11 Interim report for January - March 2021

LEX ASEA DISTRIBUTION

Moberg Pharma is distributing its shares in the subsidiary OncoZenge AB to its shareowners. The record date for the right to receive shares in OncoZenge is February 5, 2021. Ten ordinary shares in Moberg Pharma, as of the record date for the distribution, entitle to one share in OncoZenge. For more information, see the Q&A

 

SPIN-OFF AND SEPARATE LISTING OF BUPI IS ONGOING

Moberg Pharma is distributing the operations of BupiZenge® (BUPI) to the shareholders of Moberg Pharma by distributing its shares in the subsidiary OncoZenge AB through a Lex ASEA distribution before listing the OncoZenge on Nasdaq First North Growth Market where the first day of trading is expected to be on February 12, 2021. Read more at OncoZenges webpage